European Association for the Study of the Liver Congress 2025 (EASL 2025)

Liver injury occurs in around one in 20 patients treated with cyclin-dependent kinase 4/6 inhibitors for metastatic breast cancer, according to a multicentre retrospective study in Spain.

The long-acting, bivalent fibroblast growth factor 21 analogue efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) in the phase 2b SYMMETRY trial.

The addition of elebsiran, an investigational small interfering ribonucleic acid (siRNA), to pegylated interferon (PEG-IFN) alfa led to a higher rate of hepatitis B surface antigen (HBsAg) loss in patients with chronic HB virus (HBV) infection compared with PEG-IFN alfa alone, according to the ENSURE study presented at EASL 2025.

Findings from the phase III ELATIVE^® trial demonstrate that the peroxisome proliferator-activated receptor (PPAR) agonist elafibranor improves fatigue in individuals with primary biliary cholangitis (PBC), with limited correlation with pruritus.

The galectin-3 (Gal3) inhibitor belapectin, given at the established 2-mg dose, demonstrates its treatment potential for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension (PH) in the phase IIb/III NAVIGATE trial.

Treatment with resmetirom improves liver stiffness, fibrosis biomarkers, and risk scores for clinically significant portal hypertension (CSPH) in patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis at 2 years, according to a study.